



# SALDA – MDRC\_SAHpra MEETING

15 Nov 2023





*The Southern African Laboratory Diagnostics Association is a body that represents laboratory medicine in Southern Africa. It is a unified voice around In Vitro Diagnostics (IVD) and a collaboration of multinational and local companies who distribute In Vitro Diagnostic tests/equipment. SALDA has a constitution and operates under a code of ethics.*

Contact : ([exec@salda.org.za](mailto:exec@salda.org.za))

<https://salda.org.za/>

<https://www.linkedin.com/company/salda-za/>



**TANYA WILSON - CHAIRPERSON**  
The Scientific Group - Local



**MICHELLE BRONZE - VICE  
CHAIRPERSON**  
Diagnostech - Local



**GREG NORTHFIELD**  
Separation Scientific - Local



**SABINE HELLYER**  
Thermo Fisher - Multinational



**THOMAS RAFUNDISANI**  
Beckman Coulter - Multinational



**JAN KALJEE**  
SMM Instruments - Local



**DUNCAN MACKAY**  
Becton Dickinson - Multinational



**LOSHNEE VANDAYAR**  
Cepheid - Multinational



**ANDISWA LAWANA**  
Roche - Multinational



**SARAH COHEN**  
SALDA Executive Officer



**KELEBOGILE LETSWALO**  
SALDA Marketing and  
Communications Officer






## **We believe IVDs are a key contributor to support and broaden universal healthcare coverage in resource-limited environments**

### **Our Mission**

IVDs contribute to more than 70% of all medical diagnosis and can be used to decrease overall healthcare costs. We believe that broader access to innovative diagnostic tools will drive and support the healthcare paradigm.

Our association aims to lead and highlight the relevance and impact of IVD, influence patient lives and wellbeing, improve access, propel the market within Southern Africa. We actively engage with necessary stakeholders, public, private, advocacy, patient groups about the value industry brings to patients.



# Stakeholder Engagement

SALDA:




# Background



In Vitro Diagnostics are made up of various disciplines:



- Each of these is a specialisation on its own, many have requirement for quality compliance and cold chain management
- Includes Research and Development and Clinical trials/evaluation





## VODI: Value of Diagnostic Information

### HEALTHCARE SYSTEMS

#### ECONOMIC EFFICIENCIES

- Patient triage
- Avoided cost of disease progression
- Waiting time
- Avoided adverse events
- (Re-)hospitalisation
- Shift to community care

### PATIENTS

- Clinical benefit (patient safety)
- Patient empowerment
- Satisfaction
- Value of knowing and deciding

### HEALTHCARE PROVIDERS

- Turn around time
- Operational costs
- Quality (reliability, reproducibility)

### HEALTHCARE PROFESSIONALS

#### PATIENT MANAGEMENT

- Rapid, appropriate clinical response
- Avoid unnecessary, ineffective testing



- In the field of medicine, precise and rapid diagnostics are crucial for identifying diseases, monitoring treatment responses, and guiding therapeutic decisions.
- In vitro diagnostics (IVD) play a vital role in modern healthcare by enabling accurate and timely detection, monitoring, and management of various diseases and medical conditions.
- These diagnostic tests are conducted outside the living organism, typically in a laboratory setting, using patient samples like blood, urine, tissue, and other bodily fluids.
- IVD has revolutionized medical practice, leading to earlier diagnoses, personalized treatment plans, and improved patient outcomes.

In Vitro Diagnostics (IVD) has a **wide range of applications** across various areas of medicine and healthcare due to which it can witness tremendous growth in the coming years. **These include:**

- - Disease Diagnosis
- - Monitoring Disease Progression
- - Personalised Medicine
- - Drug Development and Clinical Trials
- - Blood Banking and Transfusion Medicine
- - Fertility and Pregnancy Testing
- - Point-of-Care Testing (POCT)..Etc



- Public – National Health Laboratory Services – Diagnostics, Research and Surveillance
- Private – National Pathology Group/Laboratory Medicine Group - Diagnostics
- Academic – Linked to Universities – research and innovation
- Basic research and development facilities
  - Genomics
  - Vaccine
  - Local manufacture
- Accreditation – South African National Accreditation System(SANAS)
  - ISO15189
  - GCLP (Good Clinical Laboratory Practice)
  - ISO17025
  - ISO 13485




# Challenges and Opportunities



## Regulatory Compliance

- Revised regulations /Fees
- Licensing
- ISO13485

NB . Product Registration -PENDING




## Detainments (Port Health)

- Export /Import requirements (NDOH)
- Animal products (Dept. of Agriculture)



## Footprint in Africa

- Opportunities to engage with other countries (Mecomed, GMTA, MedTech Europe) as an industry
- Understanding, consolidating, standardising regulations/ trade in each country (especially in SADC region)



## Pandemic Readiness

- Lessons from COVID to apply to other disease outbreaks, pandemics
- Opportunity to grow our industry

NB . Public Private Partnerships



- Less structured regulatory framework for IVDs in the past

WHO – use of IVDs to guide clinical decision making

- WHO pre-qualification – aim to focus on quality and performance of IVDs
- Access to safe, efficacious products and diagnostic technologies of good quality per standard requirements
- Focus is placed on IVDs for priority diseases and their suitability for use in resource-limited settings

- Pre-Qualification assessment encompasses following :

- ✓ Dossier review ( conforms to essential principles of safety and performance of MD/IVDs)
- ✓ Manufacturing Site inspection – QMS Functional - Critical areas
- ❖ Instructions for use
- ❖ Stability of products
- ❖ Training
- ❖ Complaints handling
- ✓ Laboratory evaluation
- ✓ Labelling review based on internationally recognized standards and WHO guidance and specifications.

Once evaluated, if the products are deemed compliant, they are listed as eligible for procurement on the public website.



- Performance and Operational Characteristics
- Meet acceptance criteria
  - Sensitivity
  - Specificity

## Details provided in the report :

- Product provided for evaluation
- Specimen panels tested
- Reference results
- Data Analysis
- Results
- Appraisal by laboratory personnel
- Appendices containing data generated during the evaluation

\* Product eligible for procurement if it passes the criteria above.



- Safety
- Quality
- Performance
- ✓ All critical once placed on the market and is the obligation of the manufacturer
- ✓ Need strengthened post-market vigilance process to protect patients



# Barriers to Trade and other obstacles



Regulations not streamlined across the continent.  
Need good regulatory practices ; Reliance

Heavily regulated under IVDR

Patient Impact – surge of Antimicrobial Resistance hence new technologies required

Access to IVDs: Financial disparities in SA linked to access – rural vs urban;  
WHO Resolutions – strengthening diagnostics capacity

Knock on effect of COVID-19 – lack of testing for TB/HIV etc. has led to increased cases globally impacting the IVD/ diagnostics market

POC testing /self-testing/near-patient testing/RUO





# Recommendations

- Good Regulatory Practice – Regulate only what is strictly necessary to fulfil the mandate
- Define the practical steps to regulate and group products to reduce application costs
- Determine the organisational capacity required at the company and the regulator – i.e., skills and capacity building
- Use available expertise from the industry; what about innovation
- Reliance – accept certification from selected regulators without requiring dossiers that require additional intense review
- Estimate fees required to support the planned process of registration (consider SMEs and possible banding structure)
- Adjust fees and requirements to do no harm to the sector
- Protect the access to IVDs for all South African patients



